Physician profile
Marko Bodor
NPI 1588681191
$2,599.02
in general payments reported to CMS, 2019-2025
15 companies · $15.15 in 2025
The $15.15 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,483 · 2020: $97.48 · 2021: $168 · 2022: $148 · 2023: $625 · 2024: $62.76 · 2025: $15.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,356.76 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $259.57 | 2021-2024 | Xeomin |
| Bioventus LLC | $223.68 | 2019-2024 | Gelsyn-3, Durolane |
| Spr Therapeutics, INC | $168.10 | 2023 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $155.63 | 2023 | Iovera, Zilretta |
| Avanos Medical | $148.28 | 2019 | |
| Stryker Corporation | $60.50 | 2021-2022 | |
| Samsung Hme America, INC. | $50.00 | 2023 | |
| Ferring Pharmaceuticals INC. | $45.37 | 2023-2025 | Euflexxa |
| Endo Pharmaceuticals INC. | $37.61 | 2020-2023 | Xiaflex |
| Scilex Pharmaceuticals INC. | $37.39 | 2023 | Ztlido |
| Depuy Synthes Sales INC. | $16.73 | 2023 | Orthovisc, Monovisc |
| Sonex Health, INC. | $16.68 | 2020 | |
| Pacira Therapeutics, INC. | $11.47 | 2019 | |
| Orthogenrx INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marko Bodor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.